CCL

Összesen 5 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM069431
Első szerző:Farmakis, Dimitrios
Cím:Levosimendan beyond inotropy and acute heart failure : evidence of pleiotropic effects on the heart and other organs : an expert panel position paper / Farmakis Dimitrios, Alvarez Julian, Gal Tuvia Ben, Brito Dulce, Fedele Francesco, Fonseca Candida, Gordon Anthony C., Gotsman Israel, Grossini Elena, Guarracino Fabio, Harjola Veli-Pekka, Hellman Yaron, Heunks Leo, Ivancan Visnja, Karavidas Apostolos, Kivikko Matti, Lomivorotov Vladimir, Longrois Dan, Masip Josep, Metra Marco, Morelli Andrea, Nikolaou Maria, Papp Zoltán, Parkhomenko Alexander, Poelzl Gerhard, Pollesello Piero, Ravn Hanne Berg, Rex Steffen, Riha Hynek, Ricksten Sven-Erik, Schwinger Robert H. G., Vrtovec Bojan, Yilmaz M. Birhan, Zielinska Marzenna, Parissis John
Dátum:2016
ISSN:0167-5273
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:International Journal Of Cardiology 222 (2016), p. 303-312. -
További szerzők:Alvarez, Julian Gal, Tuvia Ben Brito, Dulce Fedele, Francesco Fonseca, Candida Gordon, Anthony C. Gotsman, Israel Grossini, Elena Guarracino, Fabio Harjola, Veli-Pekka Hellman, Yaron Heunks, Leo Ivancan, Visnja Karavidas, Apostolos Kivikko, Matti Lomivorotov, Vladimir Longrois, Dan Masip, Josep Metra, Marco Morelli, Andrea Nikolaou, Maria Papp Zoltán (1965-) (kardiológus, élettanász) Parkhomenko, Alexander Poelzl, Gerhard Pollesello, Piero Ravn, Hanne Berg Rex, Steffen Riha, Hynek Ricksten, Sven-Erik Schwinger, Robert H. G. Vrtovec, Bojan Yilmaz, Mehmet Birhan Zielinska, Marzenna Parissis, John
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM070104
035-os BibID:(Wos)000405571400002 (Scopus)85020004824
Első szerző:Harjola, Veli-Pekka
Cím:Organ dysfunction, injury and failure in acute heart failure : from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) / Harjola Veli-Pekka, Mullens Wilfried, Banaszewski Marek, Bauersachs Johann, Brunner-La Rocca Hans-Peter, Chioncel Ovidiu, Collins Sean P., Doehner Wolfram, Filippatos Gerasimos S., Flammer Andreas J., Fuhrmann Valentin, Lainscak Mitja, Lassus Johan, Legrand Matthieu, Masip Josep, Mueller Christian, Papp Zoltán, Parissis John, Platz Elke, Rudiger Alain, Ruschitzka Frank, Schäfer Andreas, Seferovic Petar M., Skouri Hadi, Yilmaz Mehmet Birhan, Mebazaa Alexandre
Dátum:2017
ISSN:1388-9842
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:European Journal Of Heart Failure. - 19 : 7 (2017), p. 821-836. -
További szerzők:Mullens, Wilfried Banaszewski, Marek Bauersachs, Johann Brunner-La Rocca, Hans-Peter Chioncel, Ovidiu Collins, Sean P. Doehner, Wolfram Filippatos, Gerasimos S. Flammer, Andreas J. Fuhrmann, Valentin Lainscak, Mitja Lassus, Johan Legrand, Matthieu Masip, Josep Mueller, Christian Papp Zoltán (1965-) (kardiológus, élettanász) Parissis, John Platz, Elke Rudiger, Alain Ruschitzka, Frank Schäfer, Andreas Seferović, Petar M. Skouri, Hadi Yilmaz, Mehmet Birhan Mebazaa, Alexandre
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM076736
035-os BibID:(WoS)000501730100012 (Scopus)85075326564
Első szerző:Maack, Christoph
Cím:Treatments targeting inotropy : a position paper of the Committees on Translational Research and Acute Heart Failure of the Heart Failure Association of the European Society of Cardiology / Christoph Maack, Thomas Eschenhagen, Nazha Hamdani, Frank R. Heinzel, Alexander R. Lyon, Dietmar J. Manstein, Joseph Metzger, Zoltán Papp, Carlo G. Tocchetti, M. Birhan Yilmaz, Stefan D. Anker, Jean-Luc Balligand, Johann Bauersachs, Dirk Brutsaert, Lucie Carrier, Stefan Chlopicki, John G. Cleland, Rudolf A. de Boer, Alexander Dietl, Rodolphe Fischmeister, Veli-Pekka Harjola, Stephane Heymans, Denise Hilfiker-Kleiner, Johannes Holzmeister, Gilles de Keulenaer, Giuseppe Limongelli, Wolfgang A. Linke, Lars H. Lund, Josep Masip, Marco Metra, Christian Mueller, Burkert Pieske, Piotr Ponikowski, Arsen Ristic, Frank Ruschitzka, Petar M. Seferovic, Hadi Skouri, Wolfram H. Zimmermann, Alexandre Mebazaa
Dátum:2019
ISSN:0195-668X
Megjegyzések:Acute heart failure (HF) and in particular, cardiogenic shock are associated with high morbidity and mortality. A therapeutic dilemma is that the use of positive inotropic agents, such as catecholamines or phosphodiesterase-inhibitors, is associated with increased mortality. Newer drugs, such as levosimendan or omecamtiv mecarbil, target sarcomeres to improve systolic function putatively without elevating intracellular Ca2+. Although meta-analyses of smaller trials suggested that levosimendan is associated with a better outcome than dobutamine, larger comparative trials failed to confirm this observation. For omecamtiv mecarbil, Phase II clinical trials suggest a favourable haemodynamic profile in patients with acute and chronic HF, and a Phase III morbidity/mortality trial in patients with chronic HF has recently begun. Here, we review the pathophysiological basis of systolic dysfunction in patients with HF and the mechanisms through which different inotropic agents improve cardiac function. Since adenosine triphosphate and reactive oxygen species production in mitochondria are intimately linked to the processes of excitation-contraction coupling, we also discuss the impact of inotropic agents on mitochondrial bioenergetics and redox regulation. Therefore, this position paper should help identify novel targets for treatments that could not only safely improve systolic and diastolic function acutely, but potentially also myocardial structure and function over a longer-term.
Tárgyszavak:idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Heart failure
Acute decompensated heart failure
Inotropes
Cardiogenic shock
Excitation-contraction coupling
Calcium
Sarcomeres
Mitochondria
Energetics
Adrenergic receptors
Contractility
Levosimendan
Omecamtiv mecarbil
Nitroxyl
Megjelenés:European Heart Journal. - 40 : 44 (2019), p. 3626-3640. -
További szerzők:Eschenhagen, Thomas Hamdani, Nazha Heinzel, Frank R. Lyon, Alexander Manstein, Dietmar J. Metzger József Papp Zoltán (1965-) (kardiológus, élettanász) Tocchetti, Carlo Gabriele Yilmaz, Mehmet Birhan Anker, Stefan D. Balligand, Jean-Luc Bauersachs, Johann Brutsaert, Dirk L. Carrier, Lucie Chlopicki, Stefan Cleland, John G. Boer, Rudolf A. de Dietl, Alexander Fischmeister, Rodolphe Harjola, Veli-Pekka Heymans, Stephane Hilfiker-Kleiner, Denise Holzmeister, Johannes De Keulenaer, Gilles Limongelli, Giuseppe Linke, Wolfgang A. Lund, Lars H. Masip, Josep Metra, Marco Mueller, Christian Pieske, Burkert Ponikowski, Piotr Ristić, Arsen D. Ruschitzka, Frank Seferović, Petar M. Skouri, Hadi Zimmermann, Wolfram H. Mebazaa, Alexandre
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM040618
Első szerző:Papp Zoltán (kardiológus, élettanász)
Cím:Levosimendan : molecular mechanisms and clinical implications Consensus of experts on the mechanisms of action of levosimendan / Papp Z., Édes I., Fruhwald S., De Hert S. G., Salmenperä M., Leppikangas H., Mebazaa A., Landoni G., Grossini E., Caimmi P., Morelli A., Guarracino F., Schwinger R. H., Meyer S., Algotsson L., Wikström B. G., Jörgensen K., Filippatos G., Parissis J. T., González M. J., Parkhomenko A., Yilmaz M. B., Kivikko M., Pollesello P., Follath F.
Dátum:2012
Megjegyzések:The molecular background of the Ca(2+)-sensitizing effect of levosimendan relates to its specific interaction with the Ca(2+)-sensor troponin C molecule in the cardiac myofilaments. Over the years, significant preclinical and clinical evidence has accumulated and revealed a variety of beneficial pleiotropic effects of levosimendan and of its long-lived metabolite, OR-1896. First of all, activation of ATP-sensitive sarcolemmal K(+) channels of smooth muscle cells appears as a powerful vasodilator mechanism. Additionally, activation of ATP-sensitive K(+) channels in the mitochondria potentially extends the range of cellular actions towards the modulation of mitochondrial ATP production and implicates a pharmacological mechanism for cardioprotection. Finally, it has become evident, that levosimendan possesses an isoform-selective phosphodiesterase-inhibitory effect. Interpretation of the complex mechanism of levosimendan action requires that all potential pharmacological interactions are analyzed carefully in the framework of the currently available evidence. These data indicate that the cardiovascular effects of levosimendan are exerted via more than an isolated drug-receptor interaction, and involve favorable energetic and neurohormonal changes that are unique in comparison to other types of inodilators.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:International Journal of Cardiology. - 159 : 2 (2012), p. 82-87. -
További szerzők:Édes István (1952-) (kardiológus) Fruhwald, Sonja De Hert, Stefan G. Salmenperä, Markku Leppikangas, Heli Mebazaa, Alexandre Landoni, Giovanni Grossini, Elena Caimmi, Philippe Morelli, Andrea Guarracino, Fabio Schwinger, Robert H. G. Meyer, Sven Algotsson, Lars Wikström, Gerhard Jörgensen, Kirsten Filippatos, Gerasimos S. Parissis, John González, Martín J. Parkhomenko, Alexander Yilmaz, Mehmet Birhan Kivikko, Matti Pollesello, Piero Follath Ferenc
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

5.

001-es BibID:BIBFORM081810
035-os BibID:(cikkazonosító)1834 (WoS)000502294400077 (Scopus)85091254940 (PMID)31683969
Első szerző:Pollesello, Piero
Cím:Short-Term Therapies for Treatment of Acute and Advanced Heart Failure-Why so Few Drugs Available in Clinical Use, Why Even Fewer in the Pipeline? / Piero Pollesello, Tuvia Ben Gal, Dominique Bettex, Vladimir Cerny, Josep Comin-Colet, Alexandr A. Eremenko, Dimitrios Farmakis, Francesco Fedele, Cândida Fonseca, Veli-Pekka Harjola, Antoine Herpain, Matthias Heringlake, Leo Heunks, Trygve Husebye, Visnja Ivancan, Kristian Karason, Sundeep Kaul, Jacek Kubica, Alexandre Mebazaa, Henning Mølgaard, John Parissis, Alexander Parkhomenko, Pentti Põder, Gerhard Pölzl, Bojan Vrtovec, Mehmet B. Yilmaz, Zoltan Papp
Dátum:2019
ISSN:2077-0383
Megjegyzések:Both acute and advanced heart failure are an increasing threat in term of survival, quality of life and socio-economical burdens. Paradoxically, the use of successful treatments for chronic heart failure can prolong life but-per definition-causes the rise in age of patients experiencing acute decompensations, since nothing at the moment helps avoiding an acute or final stage in the elderly population. To complicate the picture, acute heart failure syndromes are a collection of symptoms, signs and markers, with different aetiologies and different courses, also due to overlapping morbidities and to the plethora of chronic medications. The palette of cardio- and vasoactive drugs used in the hospitalization phase to stabilize the patient's hemodynamic is scarce and even scarcer is the evidence for the agents commonly used in the practice (e.g. catecholamines). The pipeline in this field is poor and the clinical development chronically unsuccessful. Recent set backs in expected clinical trials for new agents in acute heart failure (AHF) (omecamtiv, serelaxine, ularitide) left a field desolately empty, where only few drugs have been approved for clinical use, for example, levosimendan and nesiritide. In this consensus opinion paper, experts from 26 European countries (Austria, Belgium, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, The Netherlands, Norway, Poland, Portugal, Russia, Slovenia, Spain, Sweden, Switzerland, Turkey, U.K. and Ukraine) analyse the situation in details also by help of artificial intelligence applied to bibliographic searches, try to distil some lesson-learned to avoid that future projects would make the same mistakes as in the past and recommend how to lead a successful development project in this field in dire need of new agents.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
acute heart failure
advanced heart failure
clinical development
levosimendan
regulatory clinical trials
short-term hemodynamic therapy
Megjelenés:Journal of Clinical Medicine. - 8 : 11 (2019), p. 1-18. -
További szerzők:Ben Gal, Tuvia Bettex, Dominique Cerny, Vladimir Comin-Colet, Josep Eremenko, Alexandr A. Farmakis, Dimitrios Fedele, Francesco Fonseca, Candida Harjola, Veli-Pekka Herpain, Antoine Heringlake, Matthias Heunks, Leo Husebye, Trygve Ivancan, Visnja Karason, Kristian Kaul, Sundeep Kubica, Jacek Mebazaa, Alexandre Mølgaard, Henning Parissis, John Parkhomenko, Alexander Põder, Pentti Pölzl, Gerhard Vrtovec, Bojan Yilmaz, Mehmet Birhan Papp Zoltán (1965-) (kardiológus, élettanász)
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 
Corvina könyvtári katalógus v8.2.27 © 2023 Monguz kft. Minden jog fenntartva.